Niu, N., Xue, J., Chen, G., Qiu, F., Xu, Q., Zheng, X., . . . Liu, C. Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: A randomised phase 2b trial. Nature Portfolio.
Chicago Style (17th ed.) CitationNiu, Nan, et al. Neoadjuvant ARX788 Plus Pyrotinib Versus Trastuzumab, Pertuzumab, Docetaxel and Carboplatin for HER2-positive Breast Cancer: A Randomised Phase 2b Trial. Nature Portfolio.
MLA (9th ed.) CitationNiu, Nan, et al. Neoadjuvant ARX788 Plus Pyrotinib Versus Trastuzumab, Pertuzumab, Docetaxel and Carboplatin for HER2-positive Breast Cancer: A Randomised Phase 2b Trial. Nature Portfolio.
Warning: These citations may not always be 100% accurate.